MAIA Biotechnology Announces Efficacy Updates for THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (NYSEAMERICAN: MAIA) disclosed information relating to its Phase 2 THIO-101 trial in advanced non-small cell lung cancer through a press release on February 4, 2025. According ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
MAIA Biotechnology Amends Employment Agreements with Executive Officers
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) recently disclosed updates to the employment agreements of key executive officers in a Form 8-K filing dated February 1, 2025. The company entered into ...
MAIA Biotech executives receive salary hikes and new terms
In recent company developments, MAIA Biotechnology, Inc., a pharmaceutical preparations company valued at $54.93 million, has ...
The National Law Review8m
EPA Postpones Addition of Nine PFAS to Toxics Release Inventory for Reporting Year 2025
On February 5, 2025, the U.S. Environmental Protection Agency (EPA) delayed until March 21, 2025, the effective date of a ...